Abstract
Granuloma annulare (GA) is a chronic inflammatory disease of unknown etiology characterized by the development of plaques preferentially localized to the distal extremities. Spontaneous remission and relapses are quite common and the course of GA is not easy to predict. Moreover, most therapeutic regimens have been used anecdotally and with variable success. We report the case of a 62-year-old White female patient affected by disseminated GA unsuccessfully treated with psoralen plus UVA photochemotherapy, prednisone, and cyclosporine (ciclosporin) who responded to the anti-tumor necrosis factor-a monoclonal antibody infliximab administered intravenously at a dosage of 5 mg/kg at weeks 0, 2, and 6 and thereafter at monthly intervals for 10 additional months. Most of the GA lesions improved within 8 weeks and then slowly resolved within 10 months of treatment. We suggest that infliximab may be proposed as an additional therapeutic option in the treatment of recalcitrant forms of disseminated GA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grogg KL, Nascimento AG. Subcutaneous granuloma annulare in childhood: clinicopathologic features in 34 cases. Pediatrics 2001; 107: E42
Barron DF, Cootauco MH, Cohen BA. Granuloma annulare: a clinical review. Lippincotts Prim Care Pract 1997; 1: 33–9
Smith MD, Downie JB, DiCostanzo D. Granuloma annulare. Int J Dermatol 1997; 36: 326–33
Tan HH, Goh CL. Granuloma annulare: a review of 41 cases at the National Skin Centre. Ann Acad Med Singapore 2000; 29: 714–8
Penas PF, Jones-Caballero M, Fraga J, et al. Perforating granuloma annulare. Int J Dermatol 1997; 36: 340–8
Felner EI, Steinberg JB, Weinberg AG. Subcutaneous granuloma annulare: a review of 47 cases. Pediatrics 1997; 100: 965–7
Fayyazi A, Schweyer S, Eichmeyer B, et al. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292: 384–90
Ahmed AA, Nordlind K, Schultzberg M, et al. Interleukin-1 alpha- and beta-, interleukin-6- and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions.Acta Derm Venereol 1994; 74: 435–40
Jacobi A, Manger B, Schuler G, et al. Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J Dtsch Dermatol Ges 2003; 1: 259–72
LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha: new drugs used to modulate inflammatory diseases. Dermatol Clin 2001; 19: 617–35
Tan MH, Gordon M, Lebwohl O, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930–3
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842–7
Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61: 298–304
Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548–50
Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factoralpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146–50
Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756–61
Hertl MS, Haendle I, Schuler G, et al. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 2005; 152: 552–5
Acknowledgments
No sources of funding were used to assist in the preparation of this case report. The authors have no conflicts of interest that are directly relevant to the content of this case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murdaca, G., Colombo, B.M., Barabino, G. et al. Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare. Am J Clin Dermatol 11, 437–439 (2010). https://doi.org/10.2165/11311040-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11311040-000000000-00000